Gilead Sciences (GILD +0.1%)
has rebounded off session lows, albeit on below-average volume, on the
heels of reports that the World Health Organization (WHO) plans to seek
talks with the company about wider use of remdesivir in COVID-19.
The FDA gave its emergency use nod on Friday, May 1, the first antiviral approved for the respiratory infection anywhere in the world.
https://seekingalpha.com/news/3568445-gilead-off-intraday-lows-on-who-interest-in-wider-use-of-remdesivir
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.